When faced with a seemingly insurmountable challenge, anyone can use a little extra motivation. For many of the thousands of riders participating in the Pan-Mass Challenge (PMC), held August 6 and 7, their “PMC Pedal Partner” patient gave them that extra push to conquer the next hill or fundraising milestone. For Dana-Farber patients, serving as a PMC Pedal Partner buoyed them as they moved through treatment. Together, riders and patients rallied around a shared, singular goal—a world without cancer.

This year, more than 6,000 riders raised an amazing $47 million for the 37th Pan-Mass Challenge to support research and care at Dana-Farber, for a total of $547 million since 1980. “Dana-Farber has a powerful partner in the Pan-Mass Challenge and the thousands of riders, volunteers, and donors who raise critical funds that allow our physician-scientists to pursue the most cutting-edge research,” said Dana-Farber President and CEO Laurie H. Glimcher, MD. “Without this support, many of the lifesaving initiatives pursued by our researchers would not be able to come to fruition. The PMC is saving lives.”

Participants chose from among six two-day rides and six single-day bike routes—extending from 25 miles to 192 miles—the longest of which is Sturbridge to Provincetown, Mass. For the 16th year, the PMC has paired pediatric oncology patients from the Jimmy Fund Clinic at Dana-Farber with teams of cyclists that ride in their honor. Having a PMC Pedal Partner helps to bring these riders closer to Dana-Farber’s mission and puts a personal face on the struggles patients face during a cancer diagnosis.

Team PHAT Tuesday Captain Tim Brightman cites the PMC Pedal Partner program as a motivating part of the PMC for him, his brother and teammate Mark, and the rest of the team that rides in honor of Mark and Tim’s brother, Steve. “When my brother was fighting his cancer, he visited Dana-Farber for a consultation,” said Brightman. “While he was there, he saw all the kids in the Jimmy Fund Clinic and told our mother he wished he could help in some way. So, now we ride the PMC to fulfill Steve’s wish. Having a young PMC Pedal Partner each year brings the connection full circle.”

“His year, we were lucky to have Charlotte as a PMC Pedal Partner. She really motivated us throughout our rides, especially when we saw her at the Lakeville stop,” he added. The PMC Pedal Partner Program is presented by John Hancock. “John Hancock PMC cyclists have long benefited from this wonderful program, and the friendships that it nurtures,” said Louise Santosuosso, assistant vice president, sponsorship marketing at John Hancock.

Each year, 100 percent of every rider-raised dollar is directed to research and care, thanks to presenting sponsors the Red Sox Foundation and New Balance, media partner WBZ-TV, and 200 other sponsors, as well as 4,000 volunteers who provide services and support to riders throughout the weekend. Riders’ spirits are also sustained by the cheering crowds who line the routes across the state.

“The PMC has evolves into a seasonal harvest of philanthropy where, through Dana-Farber, the bounty is shared with the world,” said Billy Starr, founder and executive director of the PMC and Dana-Farber Trustee.
Dear Friends,

This fall, we are filled with excitement at the arrival of Laurie H. Glimcher, MD, as President and CEO of Dana-Farber on Oct. 1. A renowned immunologist, Dr. Glimcher is optimistic about the future of cancer research and treatment. “There is no better place to be than Dana-Farber,” she said, noting that the future of cancer treatments lies in combination therapies uniting targeted therapies and immunotherapies. These are fields in which Dana-Farber is a pioneer and remains at the vanguard, and the momentum of our progress is driven in large part by you, our generous donors.

Our Jimmy Fund partners experienced this momentum firsthand in recent months, pushing the pace of their fundraising beyond expectations. The committed riders of the Pan-Mass Challenge, for example, raised an astonishing $47 million, a full $2 million above last year’s total. We are most fortunate and grateful that the largest athletic fundraising event in the country continues its singular dedication to the Jimmy Fund, contributing 100 percent of every rider-raised dollar to our lifesaving mission.

Stop & Shop and its Our Family Foundation, also a longtime donor with lifetime giving now reaching an incredible $65 million, saw tremendous support totaling $3.8 million to the Faculty Research Fund received in 2015. Since its inception, Dana-Farber Cancer Institute has placed an emphasis on cancer research and its applications to improve cancer outcomes. This commitment means that research is prominent in all of the Institute’s strategic decisions. The creation of a Faculty Research Fund in 2013 was an institutional initiative designed to help Dana-Farber achieve its ambitious research agenda. Since its launch, the Faculty Research Fund has raised $14.1 million, which is especially important as federal funding for cancer research remains competitive.

Support totaling $3.8 million to the Faculty Research Fund received in 2015 was applied this year to Dana-Farber’s initiatives in immunotherapy, genomics, and leukemia research to advance cancer treatments for patients. Since its inception, Dana-Farber-Cancer Institute has placed an emphasis on cancer research and its applications to improve cancer outcomes. This commitment means that research is prominent in all of the Institute’s strategic decisions. The creation of a Faculty Research Fund in 2013 was an institutional initiative designed to help Dana-Farber achieve its ambitious research agenda. Since its launch, the Faculty Research Fund has raised $14.1 million, which is especially important as federal funding for cancer research remains competitive.

Jennifer Ligibel, MD, a breast oncologist in the Susan F. Smith Center for Women’s Cancers and director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber, is the lead investigator of a potentially groundbreaking study to investigate the impact of weight loss on breast cancer recurrence. The Breast Cancer Weight Loss study, sponsored by the National Cancer Institute and the Alliance for Clinical Trials in Oncology, began in August to enroll nearly 1,200 overweight and obese women with early stage breast cancer from across the U.S. and Canada, to test if weight loss can help prevent recurrence. Despite many reports supporting a relationship between weight and breast cancer prognosis, there have been no studies examining the effect of weight loss upon the risk of recurrence. “We are thrilled to partner with Dana-Farber on this type of intervention research, helping find a link between key behavioral changes and breast cancer recurrence and potentially helping reduce the terrible burden of cancer for millions of women and their families worldwide,” said Woody Scal, chief business officer at Fitbit. To help study investigators track activity and weight loss, half of the study participants will receive a Fitbit Charge HR™ fitness tracker that delivers all-day activity tracking and continuous, wrist-based heart rate tracking; a Fitbit Aria® Wi-Fi Smart Scale that tracks weight and wirelessly syncs to the Fitbit online or mobile dashboard; and access to FitStar® by Fitbit premium software, which offers personalized video-based exercise experiences on mobile devices.

“Studies have shown that individuals who use meal replacements as part of a weight loss plan lose more weight over time,” says Ligibel. “Many people really struggle to control the portions of food that they are eating. OPTIFAST shakes take the guesswork out of determining what a serving is, allowing patients to more tightly control their calories and lose more weight.”

Jennier Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Susan S. Paresky

Dear Friends,

This fall, we are filled with excitement at the arrival of Laurie H. Glimcher, MD, as President and CEO of Dana-Farber on Oct. 1. A renowned immunologist, Dr. Glimcher is optimistic about the future of cancer research and treatment. “There is no better place to be than Dana-Farber,” she said, noting that the future of cancer treatments lies in combination therapies uniting targeted therapies and immunotherapies. These are fields in which Dana-Farber is a pioneer and remains at the vanguard, and the momentum of our progress is driven in large part by you, our generous donors.

Our Jimmy Fund partners experienced this momentum firsthand in recent months, pushing the pace of their fundraising beyond expectations. The committed riders of the Pan-Mass Challenge, for example, raised an astonishing $47 million, a full $2 million above last year’s total. We are most fortunate and grateful that the largest athletic fundraising event in the country continues its singular dedication to the Jimmy Fund, contributing 100 percent of every rider-raised dollar to our lifesaving mission.

Stop & Shop and its Our Family Foundation, also a longtime donor with lifetime giving now reaching an incredible $65 million, saw tremendous support totaling $3.8 million to the Faculty Research Fund received in 2015. Since its inception, Dana-Farber Cancer Institute has placed an emphasis on cancer research and its applications to improve cancer outcomes. This commitment means that research is prominent in all of the Institute’s strategic decisions. The creation of a Faculty Research Fund in 2013 was an institutional initiative designed to help Dana-Farber achieve its ambitious research agenda. Since its launch, the Faculty Research Fund has raised $14.1 million, which is especially important as federal funding for cancer research remains competitive.

Support totaling $3.8 million to the Faculty Research Fund received in 2015 was applied this year to Dana-Farber’s initiatives in immunotherapy, genomics, and leukemia research to advance cancer treatments for patients. Since its inception, Dana-Farber-Cancer Institute has placed an emphasis on cancer research and its applications to improve cancer outcomes. This commitment means that research is prominent in all of the Institute’s strategic decisions. The creation of a Faculty Research Fund in 2013 was an institutional initiative designed to help Dana-Farber achieve its ambitious research agenda. Since its launch, the Faculty Research Fund has raised $14.1 million, which is especially important as federal funding for cancer research remains competitive.

Jennifer Ligibel, MD, a breast oncologist in the Susan F. Smith Center for Women’s Cancers and director of the Leonard P. Zakim Center for Integrative Therapies at Dana-Farber, is the lead investigator of a potentially groundbreaking study to investigate the impact of weight loss on breast cancer recurrence. The Breast Cancer Weight Loss study, sponsored by the National Cancer Institute and the Alliance for Clinical Trials in Oncology, began in August to enroll nearly 1,200 overweight and obese women with early stage breast cancer from across the U.S. and Canada, to test if weight loss can help prevent recurrence. Despite many reports supporting a relationship between weight and breast cancer prognosis, there have been no studies examining the effect of weight loss upon the risk of recurrence. “We are thrilled to partner with Dana-Farber on this type of intervention research, helping find a link between key behavioral changes and breast cancer recurrence and potentially helping reduce the terrible burden of cancer for millions of women and their families worldwide,” said Woody Scal, chief business officer at Fitbit. To help study investigators track activity and weight loss, half of the study participants will receive a Fitbit Charge HR™ fitness tracker that delivers all-day activity tracking and continuous, wrist-based heart rate tracking; a Fitbit Aria® Wi-Fi Smart Scale that tracks weight and wirelessly syncs to the Fitbit online or mobile dashboard; and access to FitStar® by Fitbit premium software, which offers personalized video-based exercise experiences on mobile devices.

“Studies have shown that individuals who use meal replacements as part of a weight loss plan lose more weight over time,” says Ligibel. “Many people really struggle to control the portions of food that they are eating. OPTIFAST shakes take the guesswork out of determining what a serving is, allowing patients to more tightly control their calories and lose more weight.”

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development

Jennifer Ligibel, MD, is leading the first scientific study examining the effect of weight loss upon the risk of breast cancer recurrence.

Sincerely,

Susan S. Paresky
Senior Vice President for Development
A dedicated partner in the fight against cancer, HomeGoods continued its support of the Jimmy Fund with its 15th annual “HomeGoods Helps Families Fight Cancer” promotional campaign. Between June 2 and 29, HomeGoods shoppers were invited to make a gift at the register or purchase a reusable shopping bag to benefit pediatric and adult cancer care and research at Dana-Farber.

With the help of the dedicated HomeGoods staff and generous store customers, the 2016 Help Families Fight Cancer program raised an amazing $1.86 million, a 30 percent increase over the previous year. This brings the program’s lifetime support to more than $9 million.

With more than 365 HomeGoods stores nationwide participating in this year’s campaign, the off-price home fashions retailer has been a strong partner in the fight to end cancer. Each store displayed eye-catching signage featuring artwork by Jimmy Fund Clinic patients. The effort allowed shoppers across the country to join the organization in making a far-reaching impact.

“We’re proud of the long-term partnership we’ve had with Dana-Farber Cancer Institute by supporting the Jimmy Fund,” said Robyn Arvedon, HomeGoods spokesperson. “Our customers and associates have made a powerful impact on this important cause, and we are truly inspired by their commitment to helping families fight cancer.”

HomeGoods customers could join that fight by choosing to make a contribution of $1, $5, or $10 to “Help Families Fight Cancer” at the checkout register. With 100 percent of the proceeds benefiting the Jimmy Fund, shoppers’ contributions make a genuine difference to patients and families facing the disease.

Customers were also given the opportunity to purchase a reusable shopping bag for 99 cents featuring artwork by Dana-Farber’s Jimmy Fund Clinic patient Allisa Freiberger, 9, of Westwood, Mass. HomeGoods contributed 50 cents to the Jimmy Fund for each bag purchased. Allisa’s beautiful design depicts smiling clouds above a vibrant rainbow.

HomeGoods has maintained a strong commitment to Dana-Farber Cancer Institute and the Jimmy Fund for more than 15 years. Its dedication has resulted in millions of dollars raised to provide patient care and support to both pediatric and adult patients, as well as significant advances in cancer research. In 2015, HomeGoods’ incredible commitment was recognized by Dana-Farber with the naming of the HomeGoods Infusion Area in the Jimmy Fund Clinic.

The generosity of HomeGoods and its customers provides Dana-Farber with flexible funds essential to the fundamental research and patient care that represent the core of Dana-Farber’s lifesaving mission. This incredible support helps Dana-Farber pursue promising new research options, enhance patient care programs and initiatives, attract and retain the highest caliber faculty and staff, and bolster financial support services and community outreach.

HomeGoods continues strong partnership into 15th year

Remembering a pioneer in biostatistics

A year after the passing of its founder, Marvin Zelen, PhD, the Frontier Science Foundation made a $150,000 gift to Dana-Farber Cancer Institute. Supporting the DFCI-FSTR Marvin Zelen Memorial Symposium, this generous contribution is a tribute to Professor Zelen’s incredible legacy—one that underscores the importance of utilizing science in pursuit of helping others.

Zelen was a brilliant statistician who authored more than 200 scientific publications and founded the Department of Biostatistics and Computational Biology at Dana-Farber. The revolutionary statistical methods and study designs that he developed are still being used in clinical cancer trials today. His wife, Thelma, chief administrative officer and member of the Frontier Science Foundation board of directors, proudly recalls, “Marvin was always concerned that clinical trials benefit the patient first and the science second.”

When considering how to pay tribute to Zelen, the directors of the Frontier Science Foundation knew that establishing an annual symposium would be particularly meaningful since Zelen felt that “the science around clinical trials should always be critically looked at, as the underlying methodology was not yet perfect.” The creation of a symposium provides a chance for leading researchers to share new insights and innovations. This invaluable learning opportunity perfectly commemorates Zelen’s firm belief in being unyielding in the search to improve scientific processes in order to increase patient survival.

Nathanael Gray, PhD, named first Nancy Lurie Marks Professor

Nathanael Gray, PhD, has been named the first incumbent of the Nancy Lurie Marks Professorship in Medicine in the Field of Medical Oncology. The professorship was made possible through a generous gift from Nancy Lurie Marks, a longtime Dana-Farber supporter who established the Lurie Family Imaging Center and has provided much-needed funds to kidney cancer and neuro-oncology research. As the Nancy Lurie Marks Professor of Biological Chemistry and Molecular Pharmacology in the Field of Medical Oncology, Gray will lead studies driving drug development in areas such as EGFR inhibition, and train the next generation of researchers.

At a recent ceremony to celebrate Gray’s appointment were (from left) then Harvard Medical School Dean Jeffrey Flier, MD, Nancy Lurie Marks, Nathanael Gray, PhD, and Dana-Farber Chief Scientific Officer and Linde Family Professor in Medicine Barrett Rollins, MD, PhD.
Susan F. Smith Center Executive Council powers women’s cancer research

The Susan F. Smith Center Executive Council plays a vitally important role in educating women about breast and gynecologic cancers, and raising funds to support research and care at Dana-Farber’s Susan F. Smith Center for Women’s Cancers. Fueled by two inspirational events and generous individual philanthropy, the Executive Council raised $500,000 in fiscal year 2016.

In April, Institute Trustee Deborah First, Janit Greenwood, Barbara Marx, and Kathleen Whelan co-chaired the 13th annual Executive Council Breakfast at the Mandarin Oriental, Boston. There, a panel of prominent Dana-Farber physician-scientists presented the latest innovations in ovarian cancer research to more than 210 attendees.

“We are at a crossroads in treating ovarian cancer,” said Ursula Matulonis, MD, interim director of the Susan F. Smith Center and medical director of Gynecologic Oncology. “Our team is streamlining from further understanding of genetics, better clinical trials, and novel research—all of which lead to new therapy options for patients and higher survival rates.”

The seventh annual Beyond Boston Luncheon was hosted by Co-Chairs Meredith Reelton-Stac, Carie Capossela, and Pam Martin at the Wellesley Country Club last fall. More than 250 attendees learned about the Institute’s latest advances in breast cancer research and how philanthropy can improve the lives of patients.

“The state-of-the-art practices at Dana-Farber saved me from prolonged and unnecessary procedures,” said Dana-Farber patient and luncheon speaker Faye Ruppo. “They allowed me to continue teaching at Brandeis [University] and to spend cherished time with my granddaughter.”

“The remarkable women leaders of the Susan F. Smith Center Executive Council work tirelessly to create awareness around women’s cancers and to raise money for essential research that might not otherwise be conducted,” said Eric Winer, MD, chief of the Division of Women’s Cancers, director of Breast Oncology, and the Thompson Chair in Breast Cancer Research at Dana-Farber. “The Susan F. Smith Center and the Executive Council that raises critical funds to support it are the creation and legacy of Institute Trustee Susan F. Smith, who passed away in July. “Susan Smith was the epitome of hope and action here at Dana-Farber and within the wider community,” said Josh Bekenstein, chairman of the Dana-Farber Board of Trustees. “She led by example, encouraged others, and by extension, touched the lives of millions of patients and their families.”

DeLuca Foundation gift supports leukemia clinical trials

A $500,000 gift from the Frederick A. DeLuca Foundation is funding investigator-initiated clinical trials at Dana-Farber and providing resources to accelerate the delivery of new therapies for patients with leukemia. DeLuca was co-founder of Subway, the world’s largest chain of fast-food restaurants.

Under the direction of Richard Stone, MD, Dana-Farber chief of staff and program director for adult leukemia, the gift supports junior investigators who are helping to design and conduct clinical trials, identify biomarkers that will help guide the design of new therapies, and collect and process patient samples before, during, and after treatment to assess whether specific therapies work, among other activities.

“By providing the resources to help advance investigator-initiated clinical trials, the DeLuca Foundation is helping to generate new therapeutic options for patients and families struggling with this difficult disease,” said Stone.

Funding for investigator-initiated clinical trials is critical to advancing cancer research, but a persistent federal budgetary squeeze has made progress difficult. Additionally, federal funding is typically earmarked for basic scientific research rather than clinical investigation.

The DeLuca Foundation gift helps Stone and his team generate the proof-of-principle necessary to attract larger and long-term federal research grants and ultimately develop novel treatment strategies for leukemia. In the past 10 years, Dana-Farber clinical trials have been instrumental in securing federal approval of several new anti-leukemia therapies, a success that has improved the lives of countless patients and families.

“My family and I are hopeful that these funds will help Dr. Stone and his investigators find new treatments for leukemia,” said Liz DeLuca, Frederick Deluca’s wife of nearly 50 years. “Fired was privileged to be part of one of Dr. Stone’s clinical trials, and he encouraged others to participate as well to benefit patients in the future. He always liked to support people and help them improve their work. I know that Dr. Stone shares that dedication to hard work, and so my family and I are confident that this will help patients at Dana-Farber and beyond.”

Jimmy Fund Scooper Bowl® kicked off summer with its best year ever

The 34th annual Jimmy Fund Scooper Bowl® presented by Valvoline Instant Oil Change had its most successful year in history, raising more than $500,000 to support Dana-Farber Cancer Institute and the Jimmy Fund. This Boston tradition began in June 1983 on Boston Common under the summer sun with just four ice cream partners serving cup after cup of ice cream to about a thousand visitors. At this year’s event, more than 40,000 ice cream lovers devoured 28 tons of ice cream, frozen yogurt, and frozen novelties at Boston’s City Hall Plaza June 7-9.

Attendees of all ages came to enjoy delicious treats provided by the nation’s top ice cream and frozen yogurt companies, including Baskin-Robbins®, Ben & Jerry’s®, Breyers®, Delish by Walgreens, Edy’s®, Friendly’s®, HP Hood®, Vice Cream®, Yasso®, and Yuenling’s Ice Cream®. Students from 28 schools across Massachusetts gained entry to the event as a part of the Jimmy Fund Scooper Schools program, which encourages students to fundraise throughout the school year. This year, Scooper Schools raised a total of $33,000, and students celebrated their fundraising achievements with an ice cream-filled field trip to the event. Attendees also enjoyed live entertainment from 12 different acts throughout the nation’s largest all-you-can-eat ice cream festival.

Valvoline Instant Oil Change was “humbled to be the presenting sponsor of the 34th annual Jimmy Fund Scooper Bowl,” said CEO Don Smith. “We love to give back to such an incredible organization as the Jimmy Fund, and having fun while doing it is always a plus.”

Since 1983, the Jimmy Fund Scooper Bowl has raised more than $5.5 million for Dana-Farber.
CLRA fuels early stage research

The Children's Leukemia Research Association, Inc. (CLRA) has renewed its funding of pediatric leukemia research at Dana-Farber with a gift of $100,000. Founded in 1965 and a longtime supporter of the Institute, the association is proud to again sponsor the work of Kimberly Stegmaier, MD, co-director of the Pediatric Hematologic Malignancy Program and the Ted Williams Chair at Dana-Farber.

“She digs deeper to find results, and the results have been amazing,” said Anthony Pasqua, president of CLRA. “We’re happy to continue to support her.”

Previous funding from CLRA helped propel early stage research in Stegmaier’s lab that validated the protein MTHFD2 as a potential new drug target in acute myeloid leukemia (AML). This new gift will help in testing AML cells’ dependency on MTHFD2 for growth and survival.

“Through the generous support of CLRA, this research will help us understand a potentially key vulnerability in AML, and perhaps acute lymphoblastic leukemia (ALL) as well,” said Stegmaier. “With drugs that block MTHFD2 already in development, the results of our study could support clinical testing of these therapies in some of the highest-risk patients with AML and ALL.”

Pasqua’s daughter, Susan, is an AML survivor who was given less than a 1 percent chance of survival when she was diagnosed in 1980 at age 5. He is optimistic that with support of novel research like Stegmaier’s, a cure will be found.

“I think it will happen in our lifetime,” said Pasqua. “Never give up hope.”

Ellison Foundation fosters novel research with broad potential

Multiple myeloma is the second most common blood cancer behind non-Hodgkin lymphoma, yet it is currently regarded as an incurable disease. While periods of remission are achieved with drug treatment for some patients, the disease returns and relapsed patients are refractory to treatment.

Dana-Farber cancer biologist Sara Buhrlage, PhD., is studying how novel agents targeting the enzyme USP7 can increase levels of certain cancer tumor suppressors in multiple myeloma and, ultimately, be used as a pharmaceutical therapy for cancer patients. Buhrlage’s research also has widespread applications for treatment of a variety of other cancers including neuroblastoma, non-small cell lung cancer, osteosarcoma, and breast cancer.

To further this important work, the Ellison Foundation has continued its generous support of Dana-Farber and awarded Buhrlage a $224,000 grant.

“Our research is beneficial for both newly diagnosed and relapsed cases of multiple myeloma,” said Buhrlage. “With the Ellison Foundation’s gift, we can establish the therapeutic potential of USP7 and develop prototype drugs that will serve as the starting point to improve outcomes for patients with multiple myeloma and potentially other types of cancer.”

“We were impressed by Buhrlage’s novel approach to treating multiple myeloma, and in the broader implications,” said Martin Hall, trustee of the Ellison Foundation.

Nichols Family propels gastric and esophageal cancer research

When John and Susanna Nichols learned about the lack of adequate funding for gastric and esophageal cancer research, they made a generous gift to support the work of Dana-Farber’s Peter Enzinger, MD, director of the Center for Esophageal and Gastric Cancer, and Adam Bass, MD. Through this support, Enzinger and Bass are identifying the biological mechanisms driving esophageal and gastric cancer, with the goal of expanding treatment options.

“These generous funds from John and Susanna are empowering us to uncover key alterations in these diseases and allowing us to explore new, targeted therapeutic approaches,” said Bass. “We are now developing novel model systems for these cancers to expedite our ability to test new therapies.”

For instance, Enzinger and Bass are leveraging this support to test novel drugs against tumors driven by alterations to the HER2 gene, which is implicated in nearly 20 percent of gastric cancers.

“Historically, these diseases have not garnered the same level of federal funding as other cancers,” said Enzinger. “Philanthropic support, like this gift from the Nichols Family, is instrumental in filling the void and enables our center to conduct discovery science aimed at uncovering new treatments.”

“Susanna and I recognize the importance of philanthropy in driving the discoveries that have been so beneficial for our family,” said John. “Our hope is that generosity forward and support research that will help more families in the future.”

Jimmy Fund Month kicks off at Fenway with a special gift

On Aug. 9, the Boston Red Sox, Red Sox Foundation, and Red Sox Nation welcomed Larry Lucchino, chairman of the Jimmy Fund and a Dana-Farber Trustee, to commence Jimmy Fund Month at Fenway Park. Lucchino was presented with a ceremonial check to symbolize the longstanding partnership between the Boston Red Sox and the Jimmy Fund. Since the partnership began in 1953, the Boston Red Sox, Red Sox Foundation, and Red Sox Nation have helped the Jimmy Fund raise more than $125 million for Dana-Farber’s lifesaving mission.

From left: Tom Werner, chairman of the Boston Red Sox and chairman of the Red Sox Foundation Board; David Friedman, senior vice president/special counsel and government affairs for the Boston Red Sox; Sean McGrail, president of NESN and Red Sox Foundation Board member; Sam Kennedy, president of the Boston Red Sox; and Larry Lucchino, chairman of the Jimmy Fund.

On Aug. 31st, the Boston Red Sox, Red Sox Foundation, and Red Sox Nation presented a check to Kimberly Stegmaier, MD (center), CLRA President Anthony Pasqua (second from right), and members of her lab.
Stop & Shop surpasses $65 million in cumulative giving to Dana-Farber

According to the National Cancer Institute, pediatric cancer is the leading cause of disease-related death in children in the United States. But, because it makes up less than 1 percent of all cancers diagnosed each year, very little federal funding is directed toward researching new treatment options for this population of patients. Thankfully, since 1991, Stop & Shop and its customers have helped to fill this crucial funding gap in pediatric cancer research and care. Through Stop & Shop’s “Help Cure Childhood Cancer” campaign, the company and its customers make a powerful difference in the lives of young cancer patients and their families.

From June 10 through July 10, Stop & Shop customers had the opportunity to contribute to the Help Cure Childhood Cancer campaign at store checkouts. Customers who gave $3 or more received a coupon booklet. Dana-Farber Jimmy Fund Clinic patients Maddie, 7, from Canton, Mass., and Emma, 17, from Coleshore, Conn., served as ambassadors for the campaign.

This year, Stop & Shop and its Our Family Foundation presented Dana-Farber and the Jimmy Fund with a remarkable $2.9 million gift, bringing their total cumulative giving to more than $65 million. As one of Dana-Farber’s largest and most dedicated corporate partners, Stop & Shop’s ongoing funding has a significant impact in the fight against pediatric cancers.

“We are making strides in the treatment of childhood cancer,” said Lisa Diller, MD, chief medical officer, Pediatric Oncology at Dana-Farber. “Thanks in part to the incredible support of Stop & Shop and their customers, we have been able to expand our research and find new treatments for children with life-threatening cancers. With the knowledge gained from our work at Dana-Farber, the generosity of Stop & Shop will benefit children not only locally but globally.”

For example, Dana-Farber investigators have revealed key pathways driving atypical teratoid rhabdoid tumors (AT/RT), and are helping to lead a clinical trial of a new treatment regimen that resulted in the highest-ever survival rates for patients with this rare and aggressive pediatric cancer. They are now working with collaborators in Europe to launch a large-scale clinical trial to evaluate this treatment regimen for patients with newly diagnosed disease in medulloblastoma, one of the most common brain tumors in children, Dana-Farber investigators are developing therapies that specifically target the distinct drivers of different subtypes of the disease, and are leading the United States component of an international clinical trial to study a targeted therapy for pediatric patients with advanced medulloblastoma.

“I am tremendously proud of our commitment to helping eradicate children’s cancer, and overwhelmed year over year by the support we receive from our customers, associates, and friends,” said Institute Trustee James McCann, executive vice president and chief operating officer of Stop & Shop’s parent company, Ahold USA.

Pankes advance innovative thyroid cancer research

Elizabeth Panke, MD, PhD, and Thomas Panke, MD, of Cincinnati, Ohio, are committed to supporting cancer cures, in both their work as pathologists and also in their personal lives. Liz is a three-time survivor of ovarian, uterine, and thyroid cancers.

“We have a single-minded dedication and drive to advance cures for this disease,” said Liz. The Pankes are particularly interested in precision medicine—identifying the right treatment for the right patient, based on the profile of an individual’s tumor—and expanding its availability to more patients. Liz herself received precision therapies during her successful treatment for stage 4, aggressive cancer of the ovary and uterus 17 years ago.

A landmark study led by Jochen Lorch, MD, MS, director of Dana-Farber’s Thyroid Cancer Center, on his collaborative research to uncover genetic mutations in a patient’s drug-resistant thyroid cancer, inspired the Pankes to support Lorch’s work. The Pankes generously established the Panke Thyroid Cancer Research Fund with a charitable rollover gift from Tom’s individual retirement account.

“We appreciate the collaborative efforts of Dr. Lorch and Dana-Farber,” said Liz. “We want to help him find personalized treatments for other patients impacted by cancer.”

“Sequencing a cancer patient’s DNA can reveal unsuspected mutations that could drive response or resistance to certain treatments,” said Dr. Lorch. “This is precision medicine at its best and the Pankes’ generosity fuels further insight into this work.”

“We are excited to be associated with a research institution making such progress,” said Tom.

Breast Cancer Alliance propels research into metastatic disease

According to the motivated members of Breast Cancer Alliance, everyone has the ability to do something to make a difference in the fight against breast cancer.

“The passionate members of our organization are dedicated to supporting the best breast cancer researchers,” said Yonni Wattenmaker, executive director of Breast Cancer Alliance. “In this way, we ensure that these investigators can pursue the most intriguing hypotheses—the ideas most likely to result in new treatment options and better care for women with breast cancer.”

In 2016, Breast Cancer Alliance awarded more grants to Dana-Farber investigators than ever before. This support includes a $125,000 Young Investigator Award for Nikhil Wagle, MD, in addition to $100,000 Exceptional Project Awards for Rinath Jeevesohn, MD, and Jean Zhao, PhD. The researchers are all investigating different aspects of metastatic disease. Wagle is leading a national initiative to create a large database of metastatic samples by encouraging patients to sign up online. Jeevesohn is researching a newly discovered mutation among metastatic ER-positive breast cancers. Zhao is studying breast cancer brain metastases by developing laboratory models for testing novel therapies.

“I am tremendously proud of our commitment to helping eradicate children’s cancer, and overwhelmed year over year by the support we receive from our customers, associates, and friends,” said Institute Trustee James McCann, executive vice president and chief operating officer of Stop & Shop’s parent company, Ahold USA.
Hartman Family’s long-standing generosity drives immunotherapy research

For many patients with advanced blood cancers, stem cell transplants can drive disease into remission—but a large percentage face relapse or graft-versus-host disease (GVHD), a debilitating complication that arises when the donor immune system attacks a patient's tissues. At Dana-Farber Cancer Institute, world-class investigators are spearheading research into an emerging field of cancer medicine—immunotherapy—with the goal of reducing these rates of recurrence and mitigating the effects of GVHD.

Through the support of longtime donors Bernard and Elaine Hartman, Robert Soiffer, MD, chief of Dana-Farber’s Division of Hematologic Malignancies, is developing and testing drugs that can manipulate the immune system's activity to benefit patients—with often-dramatic results. For example, in a recent clinical trial of the immunotherapy sipilimumab in stem cell transplant patients with relapsed hematologic malignancies, Soiffer and his colleagues found that this therapy triggered a complete remission for some patients and reduced the cancer burden in many others. These findings suggest that this immunotherapy might represent an effective strategy for preventing relapse.

“We rely on philanthropy to speed the movement of new therapies from the laboratory and into the clinic, and Bernie and Elaine’s visionary commitment drives our work forward,” said Soiffer. “With their steadfast support, we’re making great strides toward improving outcomes for countless patients with stem cell transplants.”

Rubenstein Foundation bolsters palliative care

Patients living with cancer can suffer greatly as a result of their disease or treatment. The Lawrence J. and Anne Rubenstein Charitable Foundation is improving the quality of life for patients by investing in a new evidence-based approach at Dana-Farber that will inform treatment decisions and future research.

The foundation’s $250,000 commitment will help to implement a data collection and quality improvement initiative in the Division of Adult Palliative Care, which specializes in the management of pain and other symptoms, as well as the stress experienced by patients and their families as they live with cancer.

Under the direction of James Tulsky, MD, chair of Psychosocial Oncology and Palliative Care, the project will create a database that will document patients’ symptoms and responses to palliative care interventions.

For Rubenstein Foundation Trustee Joycellen Auritt, Andrew Cable, and Steven Perlmutter, who is also an Institute Trustee, it was precisely this evidence-based approach that attracted them to Tulsky’s plan. Although increasingly prevalent in other areas of health care, the use of accessible, high-quality measures to change the day-to-day experience of patients is relatively new among academic palliative care programs. As a result, the foundation’s investment stands to bolster palliative care at Dana-Farber and advance the profession as a whole, benefiting patients and their loved ones worldwide.

“We are pleased to help grow Dana-Farber’s excellent palliative care program into the nation’s best,” Perlmutter said, “and we are proud to partner with the Institute to ensure optimal support for patients and families facing cancer.”

Papa Gino’s and D’Angelo Grand Slam Savings for a Great Cause

Once again Papa Gino's and D’Angelo Grilled Sandwiches have partnered with the Jimmy Fund to offer Grand Slam Savings for a Great Cause at more than 280 D’Angelo and Papa Gino’s restaurants throughout New England. Continuing a tradition that started in 2009, team members asked customers for $1 to the Jimmy Fund in exchange for coupons from a variety of retailers. The program ran from July 1 through August 8, with all proceeds supporting the Jimmy Fund.

The ultimate goal is to help patients. To bring this message to life, each year’s program features a patient partner—this year, Jimmy Fund Clinic patient Stephanie, age 8, was the star. Stephanie is currently undergoing treatment for acute lymphoblastic leukemia, and she isn’t letting it get in the way of her big dreams. She loves to cook and her favorite kind of pizza is cheese. Stephanie enjoyed a special visit to the Papa Gino’s test kitchen where she exchanged tips with the chefs.

For their part, Papa Gino’s and D’Angelo staff were happy to help. Mark DeBlois, chairman and CEO at Papa Gino’s, said, “It is a privilege to support the Jimmy Fund because we know every dollar raised will make an impact at Dana-Farber.”

For more information about Dana-Farber’s Division of Hematologic Malignancies, please visit dana-farber.org/hematologic-malignancies or follow us on Facebook at facebook.com/DanaFarberCancerInstitute.
Ribbon-cutting celebrates $8.5 million Barr Program investment

A ribbon-cutting ceremony was held to celebrate new research space in the Longwood Center, made possible by an $8.5 million investment from the Claudia Adams Barr Program in Innovative Basic Cancer Research at Dana-Farber. The ceremony included a speaking program in which then Dana-Farber President and CEO Edward J. Benz Jr., MD, Dana-Farber Chief Scientific Officer Barrett Rollins, MD, PhD, and former Barr Investigator and Dana-Farber Marathon Challenge (DFMC) team member Kornelia Polyak, MD, PhD, reflected on the Barr Program’s growth since its founding in 1987 by Institute Trustees Dolores Barr Weaver and her husband, Wayne, in memory of her mother, Claudia Adams Barr. The DFMC team has raised more than $80 million for the program to date. Above, Rollins is joined by Barr Program Presidential Advisory Committee Chair Pamela Silver, PhD, and DFMC Board Chair Richard Horgan to officially open the new research space named in the Barr Program’s honor.

Gabrielle’s Angel Foundation supports promising Dana-Farber investigators

Gabrielle’s Angel Foundation for Cancer Research continued its longtime, generous support of Dana-Farber Cancer Institute with a $225,000 grant advancing the work of Dana-Farber physician-scientist Andrew Lane, MD, PhD. The grant will help fund Lane’s study analyzing how genetic mutations in G proteins may drive growth in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a blood disorder with a high risk of developing into AML.

“For 20 years, Gabrielle’s Angel Foundation has funded the most creative and cutting-edge cancer research conducted by the nation’s best and brightest physician-scientists focused on finding less-toxic treatments for patients living with leukemia, lymphoma, and related cancers,” said Christa Justus, director of grants at Gabrielle’s Angel Foundation. “Out of this year’s grantees, Dr. Lane was selected to receive our annual Janet D. Bowley Memorial Medical Research Award in recognition of the excellence of his proposed project.”

“With this notable award from Gabrielle’s Angel Foundation, my lab can pursue our central hypothesis that AML and MDS with G protein activation will be sensitive to targeted therapy,” said Lane. “This project could have immediate clinical significance.”

Dana-Farber and Gabrielle’s Angel Foundation share the same “bench-to-bedside” approach to translational cancer research, with the hope of expediting lab discoveries into clinical trials.

“We look forward to continued success stories from the excellent physician-scientists we fund at Dana-Farber,” said Justus.

Researcher aims for precision drug development with Cystic Fibrosis Foundation Therapeutics grant

Cystic fibrosis (CF) is a progressive genetic disease that causes persistent lung infections, limits patients’ ability to breathe, and has no cure. A recent $324,000 grant from Cystic Fibrosis Foundation Therapeutics (CFFT) to Dana-Farber supports the research of Christopher Ott, PhD, into comprehensive genomic strategies to further understand the biology and genetics of CF and develop more treatment options for patients. CFFT is the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation.

In CF, mutations of the CFTR gene disrupt its normal function, causing a buildup of mucus in the lungs that can lead to infections, lung damage, and respiratory failure. Rather than targeting specific mutations, Ott’s work is aimed at developing drugs that turn on the CFTR gene so that more functional protein can be made, which may improve lung function and overall symptoms for people with CF.

“We’re very excited about this work,” said Ott, “the technologies we are developing could also be applied to common cancer-related genes and proteins, opening potential avenues of therapy for cancer patients.”

We are very pleased to support the work of Dr. Ott, whose novel research approach has the potential to advance development of more effective treatments for people with cystic fibrosis and other diseases, including cancer,” said William Skach, MD, senior vice president of research affairs at the Cystic Fibrosis Foundation.

TBBCF awards new fellowship

For more than a decade, the Terri Brodeur Breast Cancer Foundation (TBBCF) has helped advance breast cancer research from its home base in Connecticut, across New England, and beyond. The foundation has supported Dana-Farber with 13 fellowships, and recently awarded a new $100,000 fellowship to Daniel Stover, MD. Scientists at the beginning of their careers often have innovative ideas to pursue that utilize the latest technology and strategies from their training; yet it can be difficult for these investigators to compete against more established investigators for funding.

“Early career investigators like Dr. Stover represent the potential of novel ideas and promise we see in the future of cancer research,” said John LaMattina, PhD, co-chair of the Terri Brodeur Breast Cancer Foundation scientific advisory committee. “Young researchers have increasingly limited options for funding. By supporting these investigators we hope to ensure that novel ideas are pursued and developed into the next generation of cancer therapies.”

Stover possesses a unique set of skills, combining computational science with cancer biology and patient care. He can see patients, study their disease in the laboratory, and analyze large sets of data. Through his fellowship, he is applying these abilities to investigating immunotherapy for estrogen receptor-positive breast cancer.

“I’m so honored to receive this fellowship award from the Terri Brodeur Breast Cancer Foundation,” said Stover. “Their support provides critical funding for my research into methods to predict which patients are likely to benefit from immune-based therapies.”
90% of all designated gifts support our Faculty Research Fund to advance Dana-Farber’s research mission

**Curing Kids Cancer drives novel research with broad potential**

Gráinne Owen’s son, Killian, loved playing sports. When Killian passed away at age 9 from acute lymphocytic leukemia, Gráinne knew that the best way to honor his life was through something he loved.

In 2005, one year after Killian’s passing, Owen launched Curing Kids Cancer, Inc., a charity that turns the customary end-of-season gift to coaches into an opportunity for teams to raise funds in their coaches’ honor.

In its first year, the Georgia-based charity raised nine times its fundraising goal, and has gone on to raise more than $8 million for pediatric cancer research.

This year, Curing Kids Cancer awarded Kimberly Stegmaier, MD, co-director of the Pediatric Hematologic Malignancy Program and the Ted Williams Chair at Dana-Farber, a $200,000 grant in support of innovative research into epigenetics—the study of modifications of DNA and proteins that alter which genes are active or inactive.

“Curing Kids Cancer’s generous support will help us to understand the cancer-promoting role of epigenetic alterations, such as mutations in the gene STAG2, which are present in 15 to 20 percent of Ewing sarcoma tumors,” said Stegmaier. “STAG2 is increasingly recognized as relevant in many cancers, so our study has the potential for broad impact.”

“Epigenetics is one of the fastest-developing areas of cancer research, and we think our support can really make a difference to push the research to the next level,” said Owen. “We’re excited about what Dr. Stegmaier is doing.”

**For Silvia Family, waiting room epiphany catalyzes a mission**

Every morning as he waited to receive radiation treatment for throat cancer, Sean Silvia saw the same people, many with children in tow. As he got to know them, he was moved by their struggles with exhaustion, transportation, and making ends meet.

“Some of them were the sole providers for their families,” recalled Silvia. “They went weeks without working and couldn’t keep up with their bills. The experience opened our eyes as to what needed to be done.”

To help patients facing financial hardship due to their diagnosis, Sean, his wife, Libby, and their children Isabel and Doyle started the Silva Family Fund for Patient Assistance. Through their contribution and gifts from other donors, they have raised more than $190,000 through events and their Giving Page on jimmyfund.org.

Administered by Deborah Toffler, MSW, LCSW, director of Patient and Family Programs and Services, the funds are available for eligible patients being treated through the Head and Neck Department. “We are deeply grateful to the Silvias and their friends for this compassionate gift,” said Toffler. “Provided solely through philanthropy, these funds help our patients meet immediate needs—groceries, lodging, and transportation—so they can focus on their treatment.”

“Cancer stops your world,” said Libby. “It’s good to give to those who really need support during treatment.”

**Family fund honors life of Lee Jordan Saltzman**

Lee Jordan Saltzman was a naturally gifted individual, seemingly always on the move. His thirst for knowledge motivated him to learn multiple languages, teach himself to play piano and ukulele, and pursue studies in Madrid and at the Culinary Institute of America. However, in July 2013, Lee experienced pain he thought might be appendicitis. It was stage IV pancreatic cancer.

“It was like a kick in the gut,” said Lee’s father, Tony Saltzman. Lee was only 27.

Given six months to live, Lee was prompted to see Robert Mayer, MD, the Stephen B. Kay Family Professor at Dana-Farber, who told Lee to go live his life and not think of a time frame.

“Dr. Mayer was always upfront and knew exactly what we were facing,” said Saltzman. “Because of his influence, Lee was inspired to keep going.”

In the 20 months before he succumbed to the cancer, Lee didn’t stop. He married his wife, Rhonda, traveled to Oktoberfest, and kept going.

To support the work of Dr. Mayer and his colleagues, the Family of Lee Jordan Saltzman made a gift of $253,000 to establish the Lee J. Saltzman Fund in Precision Medicine for Pancreatic Cancer.

“We are studying why this cancer is so hard to control and diagnose,” said Mayer. “We need to learn more about the disease. This gift from Lee’s family will help us reach that goal.”

**Ninety Nine cooks up support**

**Great Meal. Great Deal.**

The Ninety Nine Restaurant & Pub’s passion to serve extends well beyond the kitchen and dining area. For the sixth consecutive summer, Ninety Nine guests at more than 100 restaurants across the region were invited to add a gift to the Jimmy Fund as part of their check. From July 16 to August 12, the Ninety Nine successfully raised $230,000 this summer, bringing their cumulative restaurant fundraising total to $1.2 million.

The momentum to support Dana-Farber's cancer-fighting mission began in 2006 when David Lanzoni, a regional vice president who spent more than 20 years with the company, passed away from cancer. Lanzoni’s connection to his colleagues ran deep, and his professional network resembled a family. After his passing, his coworkers decided to take action to make a difference for those with cancer, and invited Ninety Nine restaurant patrons to join their efforts.

“With generous support from our employees and guests, we are able to honor David, and support Dana-Farber’s innovative cancer research and patient care,” said Charlie Noyes, president of the Ninety Nine. Ninety Nine employees, led by colleague Jim Kiley, and calling themselves “Team Lanzoni,” have raised additional millions over the years to support Dana-Farber and the Jimmy Fund through participation in the New Balance Falmouth Road Race, the Pan-Mass Challenge, mini-golf tournaments, bake sales, opportunity drawings, and more.
Theater Collections surpasses $30 million

Summer 2016 marked the 68th annual Jimmy Fund/Variety Children’s Charity Theatre Collections program at participating National Amusements and Apple Cinemas theaters in Massachusetts, Rhode Island, Connecticut, New York, New Jersey, and Ohio. Raising $338,000 between June 20 and July 28, including a generous $125,000 gift from the Regal Foundation, Theatre Collections remains a vital Jimmy Fund staple. Since 1949, participating movie theaters have shown a brief Jimmy Fund movie trailer before the start of feature films. After the trailer, volunteers and theater personnel pass collection canisters through the audience, inviting patrons to contribute to the Jimmy Fund. This year, moviegoers were also given an option to text their gift via their mobile phones.

“Our longest-running fundraising effort, Theatre Collections continues to be successful in the fight against cancer,” said Larry Lucchino, chairman of the Jimmy Fund. “We’re grateful for the volunteers who have given their time, and the many donors who have raised more than $30 million for the Jimmy Fund since 1949.”

Hollywood stars including Spencer Tracy, Bing Crosby, and Debbie Reynolds helped launch Theatre Collections by appearing in the early movie trailers. Today’s moviegoers are inspired by a trailer featuring the story of Dan Pardi, a pediatric cancer survivor 14 years after his successful treatment in the Jimmy Fund Clinic.

Money raised through the Theatre Collections program provides vital flexible funds that can be used when and where they are needed most, to advance Dana-Farber’s lifesaving mission.

CLL Global Research Foundation supports new research in the field of CLL

The CLL Global Research Foundation is committed to accelerating progress towards the control of chronic lymphocytic leukemia (CLL) and ultimately finding a cure for the disease. To accomplish this, their goal is to fund projects that translate into rapid clinical applications. The early funding from the CLL Global Research Foundation accelerates new ideas, which gives researchers the opportunity for increased funding from other sources.

The CLL Foundation awarded Dana-Farber’s Catherine Wu, MD, a $100,000 grant towards her research on early CLL. The funds will enable Wu’s team to further research into improving prediction and selection of optimal treatment strategies for patients with CLL.

“Over the past year, we have made significant progress in charting the genetic and epigenetic landscapes of CLL,” said Wu. “With the generous support from the CLL Global Research Foundation, we will be able to integrate the data we have collected and apply that knowledge to recommend better treatments for patients.”

“Dr. Wu is a bright new leader in the field of CLL research,” said Sam Pace, PhD, chief development officer, CLL Global Research Foundation. “Her current work has led to a significant advance in our understanding of the molecular basis of progressing CLL. It has been our pleasure to work with Dr. Wu and Dana-Farber to advance CLL research.”

Support for diabetes research guides new treatments

American Diabetes Association

“We are pleased to provide grant funding to brilliant scientists pursuing innovative ideas.”

— DESMOND SCHATZ, MD, president, medicine and science, American Diabetes Association

The American Diabetes Association is committed to supporting studies that will benefit people with diabetes, one of the leading causes of death in the United States. By empowering researchers to uncover key biological details about the disease and test new ideas, the American Diabetes Association hopes to expand therapeutic options and improve prevention measures.

The American Diabetes Association recently awarded Dana-Farber cell biologist Clint Tavares, PhD, a $166,356 grant to advance his type 2 diabetes research.

“Type 2 diabetes is considered a global epidemic and requires new treatments,” said Tavares. “This funding is advancing our work to evaluate a novel approach that may help decrease abnormally elevated blood glucose levels in type 2 diabetes, and prevent associated health complications, including kidney failure and heart disease.”

Tavares aims to better understand the mechanism behind novel protein inhibitors, which have shown promise in reducing blood glucose levels in preclinical studies. This knowledge will pinpoint the compounds that should be further tested in the clinical setting.

“The American Diabetes Association is committed to supporting the critical research efforts needed to prevent, treat, and cure all types of diabetes and diabetes-related complications,” said Desmond Schatz, MD, president, medicine and science, American Diabetes Association. “Through our highly selective research programs, we are pleased to provide grant funding to brilliant scientists pursuing innovative ideas at leading institutions, including Dana-Farber.”

Pacesetters recognized for early fundraising success

The first 100 walkers to reach Star Pacesetter status in the 2016 Boston Marathon® Jimmy Fund Walk presented by Hyundai were invited to an exclusive Pacesetter event in June at Fenway Park. This motivated group of walkers, who have raised $1,500 or more, enjoyed lunch, a Boston Red Sox game, and connecting with one another to share fundraising tips and traditions. Jimmy Fund Walk Hero Kate Morris attended the event with her parents, David Morris and Evelyn Krache Morris (above, right), and Amanda Carnes, RN, BSN, her nurse at Dana-Farber’s Jimmy Fund Clinic, who spoke about the incredible care Kate received.

Pictured above with Kate and her parents are her uncle Robert Davis and her aunt Martha Krache.
ne Mission may be one of Dana-Farber’s most aptly named philanthropic partners. Established in 2009 by Ashley and Ari Haseotes, the pediatric cancer foundation is driven by a singular purpose: to provide immediate relief to children and families from the daily stresses of living with cancer.

Inspired by the Haseotes’ experience with the cancer journey of their son Nicholas, who was successfully treated for leukemia, One Mission is dedicated to helping others cope with many of the same challenges their family faced. With recent gifts totaling $185,000, the foundation bolsters the Jimmy Fund Clinic’s patient and family programming. The funding provides support for shipping passes for new patients, the salary of a Child Life Specialist, and special events such as birthday parties, holiday gatherings, and the Summer Festival.

According to Ashley Haseotes, responsiveness to the needs of patients and their families remains One Mission’s top priority, leading the foundation to continually seek new ways to tailor its philanthropy. “We’re here to do whatever it takes to help kids and families get through cancer,” she said. “Our goal is to make life more livable during hospitalization, treatment, and recovery.” With One Mission’s partnership, Jimmy Fund Clinic staff continue to treat the whole patient and not just the disease, ensuring the “total patient care” that makes Dana-Farber a leader in the fight against cancer.
New England Patriots player Nate Solder and his wife, Lexi Allen, recently visited the Susan F. Smith Center for Women’s Cancers at Dana-Farber to sign footballs, distribute gift bags, and spend time with breast cancer patients like Rhonda Rutkowski, above.

THRU DECEMBER 12
Kick for Dana-Farber

This exciting program gives youth soccer teams the chance to raise funds for Dana-Farber, and to win great prizes like a Rally Tunnel experience, tickets to a New England Revolution home match, clinics with Revolution players and coaches, t-shirts, and more. Register or support a team at KickForDanaFarber.org or contact Casey Pereira for more information at 617-632-3869 or Casey_Pereira@dfci.harvard.edu.

THRU JANUARY
Dana-Farber & the Jimmy Fund’s Holiday Collection

Presented by Amica Insurance

New and exclusive cards and gifts! Celebrate the season with a tradition that conquers cancer. See the complete collection at DanaFarberHoliday.org and shop now for family, friends, and corporate clients.

ALL WINTER
Jimmy Fund Golf
Presented by Mohegan Sun

Organize a golf or mini golf tournament and enjoy a sport you love while supporting groundbreaking research and compassionate patient care at Dana-Farber. Start planning your summer or fall tournaments now! Contact Josh Belinish at 617-632-6609 or JoshBelinish@dfci.harvard.edu.

FEBRUARY 17
Palm Beach Breakfast with the Doctors

Discuss the latest breakthroughs with Dana-Farber physician-scientists at the Palm Beach Country Club, hosted by Event Chairs Robert Belfer, an Institute Trustee, his wife, Renée Belfer, Judy and Jim Harpel, and Vandi and Arthur Loring. Contact Karen Martins at 561-833-2080 or Karen_Martins@dfci.harvard.edu.

FEBRUARY 17
Palm Beach Pre-Celebration Dinner

Join us for an intimate dinner with the Institute’s pioneering physician-scientists at the Palm Beach home of Event Chairs Michele Kessler and her husband, Howard. The guest speaker is international journalist and author Tom Brokaw. Contact Karen Martins at 561-833-2080 or Karen_Martins@dfci.harvard.edu.

FEBRUARY 18
Palm Beach Discovery Celebration

Join us for the premier event of our Palm Beach season: the 26th annual Discovery Celebration featuring a special performance by David Foster. The event is hosted by Event Chairs Phyllis Krock, an Institute Trustee, and her husband, Richard, as well as Event Co-Chairs Institute Trustee Donald DeWeese and No wife, Bonnie; Renee and Robert Belfer, an Institute Trustee; Sandra Krakoff, an Institute Trustee; Tom Quick, Institute Trustee Jean Sharf and her husband, Fred; and Honorary Chairs Judie Schlager, an Institute Trustee, and her husband, Larry. Contact Karen Martins at 561-833-2080 or Karen_Martins@dfci.harvard.edu.

JANUARY 20
Chefs for Jimmy

Sample fare from Western New England’s finest chefs at Chez Josef in Agawam, Mass., at this 27th annual event benefiting the Jimmy Fund. For tickets or to learn more contact Molly Moss at 617-632-5091 or Molly_Moss@dfci.harvard.edu.

JANUARY 27 AND 28
The Resolution by PMC

Join The Resolution by PMC, an indoor cycling event from the Pan-Mass Challenge. 100% of all rider raised money goes directly to Dana-Farber Cancer Institute and the Jimmy Fund. Register to ride, volunteer, or make a gift at The-Resolution.org.